The evolving landscape of genetic biomarkers for immunotherapy in primary and metastatic breast cancer
BackgroundMajor advances have been achieved in the characterization of primary breast cancer genomic profiles. Limited information is available on the genomic profile of tumors originating from different metastatic locations in recurrent/metastatic (R/M) breast cancer, especially in Asian patients....
Saved in:
| Main Authors: | Liang Jin, Zijian Yang, Wei Tang, Pengli Yu, Rongrong Chen, Yan Xu, Jun Zhang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1522262/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Metastatic Triple Negative Breast Cancer: The New Era of Thinking
by: Mohammed Amrallah A., et al.
Published: (2021-05-01) -
The role of UBR2 in triple-negative breast cancer and its implications for immune checkpoint blockade therapy
by: Yanlin Jiang, et al.
Published: (2025-07-01) -
New progress in imaging diagnosis and immunotherapy of breast cancer
by: Jie He, et al.
Published: (2025-03-01) -
INTRAPLEURAL IMMUNOTHERAPY FOR METASTATIC PLEURISIES IN PATIENTS WITH BREAST CANCER
by: K. S. Titov, et al.
Published: (2014-09-01) -
Predictive circulating biomarkers of the response to anti‐PD‐1 immunotherapy in advanced HER2 negative breast cancer
by: Yuhan Wei, et al.
Published: (2025-03-01)